NEW YORK, Aug 28 (Reuters) - Teva Pharmaceutical Industries Ltd sued Swiss drugmaker Novartis AG and Momenta Pharmaceuticals Inc on Thursday, accusing them of infringing patents on its multiple sclerosis drug Copaxone.
The lawsuit, filed in U.S. District Court in Manhattan, claims that any generic version of Copaxone infringes patents that Teva contends are valid and enforceable.

Cambridge, Massachusetts-based Momenta said last month that the generic Copaxone application asserts that Teva's patents are invalid.

Teva is seeking to have the court declare that the defendants have infringed its patents, and that any approval of a Novartis generic not be granted until after Teva's patents expire.

The suit also seeks to prevent Novartis and Momenta from any commercial manufacture or sale of a generic Copaxone.

It asks the court to order Sandoz to withdraw its application seeking to sell the generic and award Teva monetary damages and interest to compensate it for misappropriation of Teva trade secrets as well as any further monetary relief the court deems just and proper.

The Guardian
CLICK HERE FOR FULL STORY